Price T Rowe Associates Inc C4 Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

  • $836 Billion
  • Q2 2024

A detailed history of Price T Rowe Associates Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 62,307 shares of CCCC stock, worth $371,972. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,307
Previous 2,115,477 97.05%
Holding current value
$371,972
Previous $17.3 Million 98.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$4.05 - $8.1 $8.32 Million - $16.6 Million
-2,053,170 Reduced 97.05%
62,307 $288,000
Q1 2024

May 15, 2024
SELL
$5.3 - $11.0 $2.35 Million - $4.87 Million
-443,003 Reduced 17.32%
2,115,477 $17.3 Million
Q4 2023

Feb 14, 2024
BUY
$1.18 - $6.03 $438,984 - $2.24 Million
372,021 Added 17.01%
2,558,480 $14.5 Million
Q3 2023

Nov 14, 2023
SELL
$1.81 - $3.89 $1.16 Million - $2.5 Million
-642,146 Reduced 22.7%
2,186,459 $4.07 Million
Q2 2023

Aug 14, 2023
SELL
$2.75 - $3.77 $128,614 - $176,319
-46,769 Reduced 1.63%
2,828,605 $7.78 Million
Q1 2023

May 15, 2023
SELL
$3.1 - $9.02 $154,624 - $449,908
-49,879 Reduced 1.71%
2,875,374 $9.03 Million
Q4 2022

Feb 14, 2023
SELL
$5.42 - $10.24 $210,312 - $397,342
-38,803 Reduced 1.31%
2,925,253 $17.3 Million
Q3 2022

Nov 14, 2022
SELL
$8.03 - $12.77 $11.4 Million - $18.1 Million
-1,419,107 Reduced 32.38%
2,964,056 $26 Million
Q2 2022

Aug 15, 2022
BUY
$5.06 - $26.46 $29,302 - $153,229
5,791 Added 0.13%
4,383,163 $33 Million
Q1 2022

May 16, 2022
BUY
$19.99 - $33.23 $5.85 Million - $9.72 Million
292,574 Added 7.16%
4,377,372 $106 Million
Q4 2021

Feb 14, 2022
BUY
$29.39 - $46.86 $3.73 Million - $5.95 Million
127,055 Added 3.21%
4,084,798 $132 Million
Q3 2021

Nov 15, 2021
BUY
$35.91 - $50.5 $14.8 Million - $20.9 Million
412,906 Added 11.65%
3,957,743 $177 Million
Q2 2021

Aug 16, 2021
BUY
$30.39 - $42.18 $44 Million - $61 Million
1,447,028 Added 68.98%
3,544,837 $134 Million
Q1 2021

May 17, 2021
BUY
$31.96 - $46.5 $18.1 Million - $26.4 Million
567,767 Added 37.11%
2,097,809 $77.6 Million
Q4 2020

Feb 16, 2021
BUY
$22.8 - $37.05 $34.9 Million - $56.7 Million
1,530,042 New
1,530,042 $49.4 Million

Others Institutions Holding CCCC

# of Institutions
126
Shares Held
53.8M
Call Options Held
331K
Put Options Held
145K
View Full List

About C4 Therapeutics, Inc.

CCCC Quotes by TradingView
  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $292M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email